By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

SAGE Therapeutics 

215 First Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-299-8380 Fax: 617-299-8379


SEARCH JOBS

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, brexanolone (SAGE-547), is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, in various CNS disorders. For more information, please visit www.sagerx.com.


Key Statistics


Email: contact@sagerx.com
Ownership: Public

Web Site: SAGE Therapeutics
Employees:
Symbol: SAGE
 



Industry
Biotechnology






Company News
SAGE Therapeutics (SAGE) Announces The Lancet Publishes Positive Phase II Brexanolone (SAGE-547) Clinical Data In Severe Postpartum Depression 6/13/2017 7:05:54 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 6/5/2017 7:46:37 AM
SAGE Therapeutics (SAGE) Receives Fast Track Designation For SAGE-217 For The Treatment Of Major Depressive Disorder 5/18/2017 6:23:16 AM
SAGE Therapeutics (SAGE) Announces First Quarter 2017 Financial Results And Provides Pipeline Update 5/10/2017 7:24:01 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 5/5/2017 6:42:39 AM
SAGE Therapeutics (SAGE) Announces Initiation Of Phase I Development And First Dosing Of SAGE-718 4/27/2017 5:35:19 AM
SAGE Therapeutics (SAGE) To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017 4/26/2017 6:40:48 AM
SAGE Therapeutics (SAGE) Appoints Michael Cloonan As Chief Business Officer And Expands Executive Team 4/24/2017 6:37:25 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) 4/6/2017 9:15:05 AM
SAGE Therapeutics (SAGE) Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 3/3/2017 6:55:11 AM
12345678910...
//-->